Chemotherapy Dose Shapes the Expression of Immune-Interacting Markers on Cancer Cells.
Chemo-immunotherapy
Controlled drug release
Doxorubicin
Tumor immune interaction
Journal
Cellular and molecular bioengineering
ISSN: 1865-5025
Titre abrégé: Cell Mol Bioeng
Pays: United States
ID NLM: 101468590
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
19
04
2022
accepted:
21
09
2022
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
Tumor and immune cells interact through a variety of cell-surface proteins that can either restrain or promote tumor progression. The impacts of cytotoxic chemotherapy dose and delivery route on this interaction profile remain incompletely understood, and could support the development of more effective combination therapies for cancer treatment. Here, we found that exposure to the anthracycline doxorubicin altered the expression of numerous immune-interacting markers (MHC-I, PD-L1, PD-L2, CD47, Fas, and calreticulin) on live melanoma, breast cancer, and leukemia cells in a dose-dependent manner Together, these results illustrate how standard-of-care chemotherapy, when administered in various manners, can lead to distinct expression of immunogenic markers on cancer cells. These findings may inform development of chemo-immunotherapy combinations for cancer treatment. The online version contains supplementary material available at 10.1007/s12195-022-00742-y.
Identifiants
pubmed: 36531864
doi: 10.1007/s12195-022-00742-y
pii: 742
pmc: PMC9751245
doi:
Types de publication
Journal Article
Langues
eng
Pagination
535-551Subventions
Organisme : NCI NIH HHS
ID : R01 CA223255
Pays : United States
Informations de copyright
© The Author(s) under exclusive licence to Biomedical Engineering Society 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Références
Sci Rep. 2018 Jul 24;8(1):11158
pubmed: 30042403
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Genet Vaccines Ther. 2010 Nov 01;8:7
pubmed: 21040569
Cell. 2016 Sep 22;167(1):171-186.e15
pubmed: 27641501
Front Immunol. 2016 Sep 27;7:382
pubmed: 27729910
ACS Nano. 2019 Mar 26;13(3):3083-3094
pubmed: 30835435
Cancer Res. 2011 Jul 15;71(14):4809-20
pubmed: 21646474
J Immunol. 2003 May 15;170(10):4905-13
pubmed: 12734333
Cell Death Dis. 2016 Jun 02;7(6):e2243
pubmed: 27253407
Biomaterials. 2015 May;50:30-7
pubmed: 25736493
Mol Cancer Ther. 2007 Sep;6(9):2468-76
pubmed: 17876044
Dermatopathology (Basel). 2021 Aug 03;8(3):359-370
pubmed: 34449584
Nanoscale. 2021 May 21;13(19):8998-9008
pubmed: 33973580
Cancer Res. 2004 Jan 15;64(2):711-8
pubmed: 14744789
Cancer Immunol Immunother. 2022 Dec;71(12):2957-2968
pubmed: 35524791
J Clin Oncol. 2009 Dec 10;27(35):5911-8
pubmed: 19805669
Oncoimmunology. 2014 Dec 13;3(9):e955691
pubmed: 25941621
Oncoimmunology. 2013 Dec 1;2(12):e26860
pubmed: 24498559
Mol Ther Methods Clin Dev. 2019 Jan 29;13:154-166
pubmed: 30788384
Nat Commun. 2020 Nov 10;11(1):5696
pubmed: 33173046
Cancer Res. 2014 May 15;74(10):2663-8
pubmed: 24778417
Clin Oncol (R Coll Radiol). 2007 Feb;19(1):23-37
pubmed: 17305252
Int J Mol Sci. 2021 Dec 21;23(1):
pubmed: 35008457
Nat Rev Mater. 2016 Dec;1(12):
pubmed: 29657852
Nat Med. 2009 Oct;15(10):1170-8
pubmed: 19767732
Macromol Biosci. 2022 Feb;22(2):e2100353
pubmed: 34762334
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Nat Commun. 2021 Apr 23;12(1):2425
pubmed: 33893275
Blood. 2016 Dec 29;128(26):3113-3124
pubmed: 27802968
Cell Death Dis. 2010 Dec 02;1:e104
pubmed: 21368877
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Anticancer Res. 2006 Jul-Aug;26(4A):2701-5
pubmed: 16886680
Cancer Res. 2013 Apr 15;73(8):2493-504
pubmed: 23418322
Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19590-5
pubmed: 23150549
Sci Signal. 2021 Oct 19;14(705):eabc4764
pubmed: 34665642
Mol Imaging Biol. 2013 Feb;15(1):40-7
pubmed: 22588595
PLoS One. 2012;7(8):e42293
pubmed: 22876313
Semin Immunol. 2010 Jun;22(3):132-43
pubmed: 20356763
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Nat Rev Drug Discov. 2012 Feb 03;11(3):215-33
pubmed: 22301798
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Cancer Cell. 2010 Aug 9;18(2):160-70
pubmed: 20708157
Biomaterials. 2022 Feb;281:121329
pubmed: 34954588
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
Nat Biomed Eng. 2020 Jan;4(1):40-51
pubmed: 31937942
Clin Cancer Res. 2007 Jan 1;13(1):341-9
pubmed: 17200373
Br J Cancer. 2002 Apr 22;86(8):1297-302
pubmed: 11953888
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
Cancer Res. 2011 Jul 15;71(14):4821-33
pubmed: 21602432
Mater Sci Eng C Mater Biol Appl. 2016 May;62:927-42
pubmed: 26952500
Ann Oncol. 2017 Dec 1;28(suppl_12):xii18-xii32
pubmed: 29045511
PLoS One. 2010 Apr 28;5(4):e10365
pubmed: 20442777
Cancer Immunol Immunother. 2010 Feb;59(2):279-91
pubmed: 19727719
J Exp Med. 2005 Dec 19;202(12):1691-701
pubmed: 16365148
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33827904
AAPS J. 2015 Jan;17(1):184-93
pubmed: 25331103
Nat Immunol. 2022 Apr;23(4):487-500
pubmed: 35145297
Science. 2016 May 6;352(6286):658-60
pubmed: 27151852
Int J Mol Sci. 2020 Apr 23;21(8):
pubmed: 32340166
BMC Cancer. 2017 Oct 16;17(1):684
pubmed: 29037232
Cell Death Differ. 2014 Jan;21(1):15-25
pubmed: 23787994
Oncoimmunology. 2018 Mar 26;7(7):e1446720
pubmed: 29900064
Sci Transl Med. 2016 Apr 13;8(334):334ra52
pubmed: 27075626
J Clin Oncol. 2012 May 1;30(13):1553-61
pubmed: 22473167
Research (Wash D C). 2022 Feb 8;2022:9768687
pubmed: 35233535
Cancer Discov. 2021 Mar;11(3):599-613
pubmed: 33334730